CTMX stock pulls back after 5-year high: Share sale sparks dilution fears despite Wall Street’s 150% upside calls
・The company launched a $250 million share sale, with the potential to raise an additional $37.5 million, to fund the development of its lead cancer drug, Varseta-M. ・Positive trial data showed that Varseta-M achieved response rates of up to 32% and...
Stocktwits